A new mega-database of half a million mutations may flag new ways of treating genetic disease, scientists say.

The dire circumstances facing cystic fibrosis patients in Cuba have come to light through a heartfelt letter sent to our news ...

The FDA has approved Alyftrek for patients aged 6 years and older with cystic fibrosis with certain mutations, according to a press release from Vertex Pharmaceuticals. The FDA has approved ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals’ ALYFTREK™ for treating cystic fibrosis in individuals aged six and older with specific gene mutations. This approval marks a ...

Vertex Pharmaceuticals Inc. notched two FDA victories on Friday for its cystic fibrosis medicines, increasing the number of patients eligible for its drugs and likely boosting its own future revenue.

The FDA has approved Vertex’s Alyftrek, a once-daily triple combination for the treatment of cystic fibrosis in people 6 years and older who have mutations that are amenable to the therapy ...

Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis ... of Trikafta by covering all mutations included in its label, along ...

Lupin Ltd received tentative approval from the USFDA for its generic version of Ivacaftor oral granules, used for treating cystic fibrosis. The product, produced at Lupin's Nagpur facility, may ...

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis. Alyftrek is a once-daily ...